Lombard Medical Technologies PLC Director/PDMR Shareholding (7722A)

TIDMLMT

RNS Number : 7722A

Lombard Medical Technologies PLC

25 March 2013

Lombard Medical Technologies PLC

("Lombard Medical" or "the Company")

Director/PDMR Shareholding

London, UK, 25 March 2013- Lombard Medical Technologies PLC (AIM: LMT), the specialist medical technology company focused on innovative vascular products, announces that following the admission to AIM on 22 March 2013 of 10,040,000 shares issued pursuant to the Second Placing and the Second Tranche Subscription of the May 2011 fundraising, certain Directors of the Company subscribed for new ordinary shares of 20 pence each in the Company ("Ordinary Shares"). The resulting interests of the Directors are set out below:

 
 Name                 Number of Ordinary   Number of Ordinary       Percentage 
                       Shares subscribed          Shares held        of issued 
                           for under the        following the    share capital 
                          Second Tranche          Transaction 
                            Subscription 
 John Rush                         4,000               12,142            0.04% 
 Simon Hubbert                     4,000                7,142            0.02% 
 Peter Phillips                    6,000               12,214            0.04% 
 Simon Neathercoat                 4,000               19,297            0.06% 
 Martin Rothman                    4,000               30,198            0.10%

- Ends -

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused on device solutions for the $1.2 billion dollar per annum abdominal aortic aneurysm (AAA) repair market. AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for this application is expected to grow to $1.6 billion by 2015. The Company's lead product, Aorfix(TM), is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy which is often present in advanced AAA disease. Aorfix(TM) is currently being commercialised in the EU, and has been approved by the FDA in the US

The Company is headquartered in Oxfordshire, with operations in Ayrshire and Phoenix, USA.

Further background on the Company can be found at www.lombardmedical.com.

For further information:

 
 Lombard Medical Technologies PLC          Tel: 01235 750 800 
 Simon Hubbert, Chief Executive Officer 
  Ian Ardill, Chief Financial Officer 
 Canaccord Genuity Limited                 Tel: 020 7523 8000 
  Lucy Tilley/ Henry Fitzgerald O'Connor 
  / Tim Redfern 
 FTI Consulting                            Tel: 020 7831 3113 
  Simon Conway / Susan Stuart / Victoria 
  Foster Mitchell

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBBGDXIGDBGXU

Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Oct 2024 to Nov 2024